Merck & Company Inc

This pharmaceutical company is responsible for one of the best-selling drugs worldwide. Their blockbuster drug, Keytruda, is designed to treat certain types of cancer and is the company’s main revenue driver. They are also behind the development of Gardasil—a vaccine for HPV that has helped prevent hundreds of thousands of cases of cervical cancer.

$89.76
(as of Mar 31, 7:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Merck & Company Inc

Stock Price
$89.76
Ticker Symbol
MRK
Exchange
NYSE

Industry Information for Merck & Company Inc

Sector
Healthcare
Industry
Drug Manufacturers - General

Company Description for Merck & Company Inc

Country
USA
Full Time Employees
73,000

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Fundamentals for Merck & Company Inc

Market Capitalization
$225,398,571,008
EBITDA
$29,134,000,128
Dividends per Share
$3.08
P/E Ratio
13.24
Forward P/E Ratio
9.91
Earnings per Share
$6.74
Earnings per Share Estimate Next Year
Profit Margin
26.67%
Shares Outstanding
2,526,040,064
Percent Owned by Insiders
0.07%
Percent Owned by Institutions
80.44%
52-Week High
52-Week Low

Technical Indicators for Merck & Company Inc

50-Day Moving Average
200-Day Moving Average
RSI
44.41
2.21

Analyst Ratings for Merck & Company Inc

Strong Buy
15
Buy
5
Hold
8
Sell
0
Strong Sell
0

News About Merck & Company Inc

Mar 31, 2025, 1:13 PM EST
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. See more.
Mar 31, 2025, 12:00 PM EST
LOS ANGELES, March 31, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming April 14, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Merck & Co (“Merck” or the “Company”) (NYSE: MRK) securities between February 3, 2022, to February 3, 2025, inclusive (the “Class Period”). See more.
Mar 30, 2025, 8:42 AM EST
NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- See more.
Mar 30, 2025, 7:03 AM EST
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options See more.